SOTIO

We’re proud to see SOTIO’s research published in @NaturePortfolio Communications. The study highlights the potential of NKG2A inhibition to restore NK cell function and strengthen anti-tumor immune responses in #ovariancancer, further advancing the understanding of novel immunotherapy approaches. Congratulations to the researchers and collaborators involved in this important achievement! Check out more here: linkedin.com/posts/jitka-fu… #CancerImmunology #OncologyInnovation #DrugDevelopment

On #ClinicalTrialsDay, we join the global research community in celebrating the theme of “Research Rising,” which honors the progress, people, and purpose that drive clinical research forward. At SOTIO, we bring deep expertise in clinical development, working to translate scientific insights into meaningful treatment options for patients. We are advancing a pipeline of #ADCs focused on initiating clinical trials for cancers where patients continue to face significant unmet need. Together, we’re helping research rise to meet the needs of today and the promise of tomorrow. @ACRPDC #CTD2026 #ResearchRising #WeAllRiseTogether #DrugDevelopment #ADCs

SOTIO is heading to #ASCO26! We look forward to engaging with oncology researchers, industry leaders and investors about our #ADCs SOT106 and SOT109 entering the clinic later this year. If you’re attending, please reach out to Radek Spisek, CEO, Vivi Boura, CMO, and Martin Vodak, Business Development Senior Director. #ASCO26 #BiotechPartnering #DrugDiscovery

Bio€quity Europe 2026, organized by @BioCentury , @EBDgroup and Prague.bio, brought together an inspiring community of innovators, investors, and partners from across the global biotech ecosystem to our home of Prague. Our CEO, Radek Spisek, presented details on our growing pipeline and participated in a panel discussion, making it a valuable opportunity for SOTIO to connect with peers, discuss the latest industry developments, and showcase recent progress across our programs, including our next-gen #ADCs. Check out some snapshots from the event below. #BioEquityEurope #DrugDiscovery #OncologyInnovation

Next stop – Greece for the @FEBSnews Tumor Microenvironment meeting. SOTIO scientist Artemis Angelidou will present work combining both spatial and immune profiling to help predict response to immunotherapy in non-small cell lung cancer (#NSCLC) -- part of our continuing dedication to developing better treatment approaches for solid tumors like lung cancer. #FEBS #DrugDevelopment #OncologyResearch

Next week, Bio€quity Europe, hosted by @BioCentury and @EBDgroup, takes center stage in our hometown. In addition to participation in the CEO’s discussion panel, Radek Spisek will present recent progress across our development pipeline of next generation #ADCs and immunocytokines on Tuesday, May 5th. If you’re interested in connecting please reach out to: partnering@sotio.com and our team attending, Radek Spisek, Norbert Prenzel, Martin Vodak or @RichardKapsa. #BioEquityEurope #DrugDevelopment #OncologyResearch #BiotechPartnering

Radek Spisek, CEO, and Norbert Prenzel, Head of Business Development, are heading to San Diego, CA, for the upcoming @AACR Annual Meeting. As we rapidly expand our clinical pipeline with next-generation #ADCs, we look forward to connecting with partners and investors to explore new opportunities for collaboration. If you’re attending and would like to meet, please reach out. #AACR2026 #BiotechPartnering #OncologyInnovation

Next month, Prague will welcome the global biotech community for Bio€quity Europe, organized by @BioCentury and @EBDgroup. Our CEO, Radek Spisek, will join a panel discussion focused on a critical topic for growing biotech companies: how to build, support, and retain strong teams across geographies. From competing with established hubs to fostering culture internationally, the session will explore practical approaches to developing talent in an increasingly global landscape. Learn more about the event here: conferences.biocentury.com/bioequity-euro… #BioEquityEurope #DrugDevelopment #CancerResearch

Norbert Prenzel, Head of Business Development and Licensing, will be in Munich for the upcoming Germany – China Pharma and Life Sciences Collaboration Forum. He’ll join a panel focused on exploring emerging trends in the global BD&L sector, particularly in high-growth areas like #ADCs and advanced therapies. #DrugDevelopment #BiotechCollaboration #HealthcareInnovation

Our Business Development team is heading to Lisbon later this month for #BIOEuropeSpring and @LSXLeaders. As we continue to advance our pipeline of next-generation #ADCs, we look forward to meeting with potential partners and investors. Please reach out to Martin Vodak or Norbert Prenzel if you’re attending and would like to meet. @EBDGroup #BIOEurope #BiotechPartnering #OncologyInnovation #CancerTherapy #LSX

Understanding the tumor microenvironment is essential for unlocking new therapeutic strategies in #oncology. At the upcoming @EACRnewsTumour Ecosystem: From Mechanisms to Novel Therapeutics Conference, SOTIO Scientist Cecilia Aquino-Perez will present research on tertiary lymphoid structures in HPV-induced cancers, showing how immune architecture within tumors shapes treatment response. We look forward to sharing our work and engaging with fellow scientists, clinicians, and translational researchers driving progress across the oncology community. #EACR26 #CancerResearch #DrugDevelopment

On #InternationalWomensDay, we acknowledge the important contributions of women across SOTIO and the broader R&D community. Their expertise and leadership strengthen our teams and support the development of innovative, patient‑focused #cancer therapies. To learn more about our culture and meet some of the colleagues driving our mission forward, check out this video: linkedin.com/feed/update/ur… #IWD2026 #WomenInSTEM #DrugDevelopment

SOTIO is attending #ESMOSarcoma next week to meet with others working at the forefront of treating #sarcoma, and share the latest exciting data on our ADC in development for sarcoma, SOT106. Please reach out to our colleagues Vivi Boura or Norbert Prenzel if you’re interested in connecting. @myESMO #RareCancers #Oncology #DrugDevelopment

#ColorectalCancer is now the leading cause of cancer-related death among people younger than 50 in the U.S. It’s a critical moment for #ColorectalCancerAwarenessMonth to spread the word and help drive earlier diagnosis and treatment. We’re developing SOT109, a next generation #ADC designed to target CDH17, an antigen that is highly expressed in colorectal cancer and other GI cancers. Check out how ADCs like our SOT109 program work to address cancers like colorectal cancer below. Learn more about colorectal cancer’s rise in the @AmericanCancer recent report: pressroom.cancer.org/under-50-morta… #DrugDevelopment #AntibodyDrugConjugates

In the article below, Chief Scientific Officer, Amy Jensen-Smith, shares her perspective on the urgent unmet need in #sarcoma and why advancing researching in this complex disease area is so critical, especially on #RareDiseaseDay. SOTIO is committed to developing precision-based therapies for sarcoma, exemplified through SOT106, our investigational antibody-drug conjugate (#ADC) targeting LRRC15, a clinically validated target broadly expressed across sarcoma subtypes. 👉 linkedin.com/posts/amy-jens… #RareDiseaseDay2026 #RareDiseases #RareCancers #OncologyDevelopment